Kiran Maski1, Lynn Marie Trotti2, Suresh Kotagal3, R Robert Auger4, Todd J Swick5, James A Rowley6, Sarah D Hashmi7, Nathaniel F Watson8. 1. Department of Neurology, Boston Children's Hospital, Boston, Massachusetts. 2. Department of Neurology, Emory University School of Medicine, Atlanta, Georgia. 3. Department of Neurology, Mayo Clinic, Rochester, Minnesota. 4. Department of Psychiatry and Psychology, Mayo Clinic College of Medicine, Rochester, Minnesota. 5. Neuroscience's Clinical Division, Takeda Pharmaceuticals. 6. Department of Medicine, Wayne State University School of Medicine, Detroit, Michigan. 7. American Academy of Sleep Medicine, Darien, Illinois. 8. Department of Neurology, University of Washington School of Medicine, Seattle, Washington.
Abstract
INTRODUCTION: This systematic review provides supporting evidence for the accompanying clinical practice guideline on the treatment of central disorders of hypersomnolence in adults and children. The review focuses on prescription medications with U.S. Food & Drug Administration approval and nonpharmacologic interventions studied for the treatment of symptoms caused by central disorders of hypersomnolence. METHODS: The American Academy of Sleep Medicine commissioned a task force of experts in sleep medicine to perform a systematic review. Randomized controlled trials and observational studies addressing pharmacological and nonpharmacological interventions for central disorders of hypersomnolence were identified. Statistical analyses were performed to determine the clinical significance of all outcomes. Finally, the Grading of Recommendations Assessment, Development and Evaluation (GRADE) process was used to assess the evidence for the purpose of making specific treatment recommendations. RESULTS: The literature search identified 678 studies; 144 met the inclusion criteria and 108 provided data suitable for statistical analyses. Evidence for the following interventions is presented: armodafinil, clarithromycin, clomipramine, dextroamphetamine, flumazenil, intravenous immune globulin (IVIG), light therapy, lithium, l-carnitine, liraglutide, methylphenidate, methylprednisolone, modafinil, naps, pitolisant, selegiline, sodium oxybate, solriamfetol, and triazolam. The task force provided a detailed summary of the evidence along with the quality of evidence, the balance of benefits and harms, patient values and preferences, and resource use considerations. CITATION: Maski K, Trotti LM, Kotagal S, et al. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment. J Clin Sleep Med. 2021;17(9):1895-1945.
INTRODUCTION: This systematic review provides supporting evidence for the accompanying clinical practice guideline on the treatment of central disorders of hypersomnolence in adults and children. The review focuses on prescription medications with U.S. Food & Drug Administration approval and nonpharmacologic interventions studied for the treatment of symptoms caused by central disorders of hypersomnolence. METHODS: The American Academy of Sleep Medicine commissioned a task force of experts in sleep medicine to perform a systematic review. Randomized controlled trials and observational studies addressing pharmacological and nonpharmacological interventions for central disorders of hypersomnolence were identified. Statistical analyses were performed to determine the clinical significance of all outcomes. Finally, the Grading of Recommendations Assessment, Development and Evaluation (GRADE) process was used to assess the evidence for the purpose of making specific treatment recommendations. RESULTS: The literature search identified 678 studies; 144 met the inclusion criteria and 108 provided data suitable for statistical analyses. Evidence for the following interventions is presented: armodafinil, clarithromycin, clomipramine, dextroamphetamine, flumazenil, intravenous immune globulin (IVIG), light therapy, lithium, l-carnitine, liraglutide, methylphenidate, methylprednisolone, modafinil, naps, pitolisant, selegiline, sodium oxybate, solriamfetol, and triazolam. The task force provided a detailed summary of the evidence along with the quality of evidence, the balance of benefits and harms, patient values and preferences, and resource use considerations. CITATION: Maski K, Trotti LM, Kotagal S, et al. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment. J Clin Sleep Med. 2021;17(9):1895-1945.
Authors: R Poryazova; S Tartarotti; R Khatami; C R Baumann; P Valko; U Kallweit; E Werth; C L Bassetti Journal: Eur Neurol Date: 2011-03-08 Impact factor: 1.710
Authors: Jonathan R L Schwartz; Neil T Feldman; Richard K Bogan; Michael T Nelson; Rod J Hughes Journal: Clin Neuropharmacol Date: 2003 Sep-Oct Impact factor: 1.592
Authors: Kiran Maski; Lynn Marie Trotti; Suresh Kotagal; R Robert Auger; James A Rowley; Sarah D Hashmi; Nathaniel F Watson Journal: J Clin Sleep Med Date: 2021-09-01 Impact factor: 4.324
Authors: Yves Dauvilliers; Richard K Bogan; Karel Šonka; Markku Partinen; Nancy Foldvary-Schaefer; Michael J Thorpy Journal: Nat Sci Sleep Date: 2022-03-29
Authors: Clete A Kushida; Colin M Shapiro; Thomas Roth; Michael J Thorpy; Bruce C Corser; Akinyemi O Ajayi; Russell Rosenberg; Asim Roy; David Seiden; Jordan Dubow; Yves Dauvilliers Journal: Sleep Date: 2022-06-13 Impact factor: 6.313